Application of 18F-fluorodeoxyglucose positron emission tomography in diagnosis of malignant diseases.
OBJECTIVE
To testify the efficacy of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the diagnosis of cancer.


METHODS
A total of 170 patients with diagnosed cancer or suspicious cancer were enrolled in this study, and underwent 18F-FDG PET. The standard uptake value (SUV) and diameter for each abnormal region in PET images were analyzed. All data were analyzed by SPSS 11.5.


RESULTS
PET scan identified a primary cancer in 45.8% (11/24) patients. The sensitivity and specificity of PET scan in differentiating malignant lesions from benign ones were 78.8% (52/66) and 77.1% (27/35) respectively. Twenty-nine out of 68 (42.6%) lesions were detected earlier by PET than by computed tomography. The SUV of primary cancer was significantly higher than that of metastatic lymph nodes (5.84 +/- 3.12 vs. 3.14 +/- 2.24, P<0.001). And SUV of primary lung cancer was also significantly higher than that of metastatic lung cancer (6.30 +/- 3.01 vs. 2.86 +/- 2.37, P<0.01).


CONCLUSIONS
18F-FDG PET plays a very important role in cancer diagnosis.
Ning
Xiao-hong
XH
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Meng
Qiu-li
QL
Wang
Yu-zhou
YZ
Bai
Chun-mei
CM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000175:diagnosis* / Q000473:pathology; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000378:metabolism*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D055815:Young Adult
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18